Has Katherine Labiner received payments from drug or device companies?

Yes. Drug and device makers reported $163,222 in general payments to Katherine Labiner across 1,055 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Katherine Labiner did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Katherine Labiner come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Katherine Labiner

Epilepsy · Austin, TXNPI 1861788465

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (38.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 33.0% of the total. 2025 is the largest year on record at $77,740, more than ten times the $3,257 reported in 2019. Among epilepsy clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$163,222in general payments, 2019–2025

Across 1,055 payments — averaging $154.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acadia Pharmaceuticals Inc$54K
UCB, Inc.$29K
Jazz Pharmaceuticals Inc.$17K
Aucta Pharmaceuticals, Inc.$16K
Neurelis, Inc.$12K
Otter Pharmaceuticals, LLC$11K
plus $25K from 54 others

$152,023in research payments, 2019–2025

Across 33 payments — averaging $4606.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$97K
Biohaven Pharmaceutical Holding Company Ltd.$49K
UCB SA$7K

What the payments were for

Consulting fees$60,35037%
Speaking & faculty fees$62,63138%
Travel & lodging$14,5229%
Food & beverage$25,64616%
Education$730%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acadia Pharmaceuticals Inc	132	$53,830
UCB, Inc.	144	$29,351
Jazz Pharmaceuticals Inc.	54	$16,821
Aucta Pharmaceuticals, Inc.	26	$15,729
Neurelis, Inc.	87	$11,580
Otter Pharmaceuticals, LLC	28	$11,056
Aquestive Therapeutics, Inc.	51	$10,926
SK Life Science, Inc.	98	$4,295
Greenwich Biosciences, Inc.	20	$816
Neuropace, Inc.	21	$801
Upsher-smith Laboratories LLC	21	$766
Biocodex, Inc.	16	$698
Livanova USA, Inc.	35	$697
Tris Pharma Inc	35	$645
Supernus Pharmaceuticals, Inc.	51	$585
Takeda Pharmaceuticals U.S.A., Inc.	31	$447
Corium, LLC	18	$347
Ironshore Pharmaceuticals Inc.	22	$328
Eisai Inc.	13	$257
Amgen	12	$226
Pyros Pharmaceuticals, Inc.	9	$217
Zogenix Inc.	10	$208
Ipsen Biopharmaceuticals, Inc	9	$200
Neos Therapeutics, LP	12	$187
Abbott	2	$183
Sunovion Pharmaceuticals Inc.	11	$149
Sumitomo Pharma America, Inc.	9	$139
Biogen	6	$130
Biohaven Pharmaceuticals, Inc.	5	$127
GSK	1	$122
Octapharma USA, Inc.	5	$99
Vertical Pharmaceuticals, LLC	4	$89
Immedica Pharma US, Inc.	3	$83
Biohaven Pharmaceutical Holding Company Ltd.	4	$81
AbbVie	4	$78
Collegium Pharmaceutical, Inc.	4	$76
Saol Therapeutics Inc.	4	$76
Antares Pharma, Inc.	3	$61
Johnson & Johnson	2	$55
Springworks Therapeutics, Inc.	2	$53
Merz Pharmaceuticals, LLC	2	$52
Mallinckrodt Hospital Products Inc.	2	$45
Amneal Pharmaceuticals LLC	3	$41
Sanofi	2	$37
Avion Pharmaceuticals	2	$35
ITF Therapeutics LLC	1	$35
Piramal Critical Care	2	$34
Nobelpharma America, LLC	2	$34
Catalyst Pharmaceuticals, Inc.	2	$33
Azurity Pharmaceuticals, Inc.	1	$30
PTC Therapeutics, Inc.	1	$28
Arbor Pharmaceuticals, Inc.	2	$27
Tersera Therapeutics LLC	1	$25
E.r. Squibb & Sons, L.L.C.	1	$25
Adlon Therapeutics L.p.	1	$24
Noven Therapeutics, LLC	1	$23
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)	1	$21
Novartis	1	$19
Aprecia Pharmaceuticals, LLC	1	$14
Genentech USA, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAYBUE$51,696
SYMPAZAN$16,574
Motpoly XR$15,500
Epidiolex$13,140
VALTOCO$10,043
LIBERVANT$3,978
Fintepla$520
XCOPRI$382
DIACOMIT$246
VNS Therapy$150
VIGADRONE$137
VNS THERAPY SENTIVA MODEL 1000 GENERATOR$127
BENLYSTA$122
OCTRODE$117
Nayzilam$106

How this compares

$163,222 in reported general payments places this provider in the 95th percentile of 36 epilepsy providers in Texas.

See all epilepsy providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobazam	13	$1,227

Paid to pharmacies, not to this prescriber.

Other epilepsy in Austin

Karen KeoughAustin$474K
Daniel GustkeyAustin$12K
Andrew LinAustin$42
Jay HarveyDallas$19K
Charles SzaboSan Antonio$15K
Erin FiedlerDallas$9K
Linda LearySan Antonio$9K
Leonel EstofanEdinburg$9K
Bernhard SuterHouston$6K
Irfan AliHouston$6K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →